Want to see CODX full AI Analyst Report?

Co-Diagnostics (CODX) Price & Analysis

1,686 Followers

CODX Stock Chart & Stats

$2.10

-$0.06(-2.86%)

At close: Jul 27 4:00 PM EDT

$2.10

-$0.06(-2.86%)

Day’s Range― - ―

52-Week Range$0.94 - $46.50

Previous Close$2.03

Volume162.41K

Average Volume (3M)10.09M

Market Cap

$6.88M

Enterprise Value$11.51

Total Cash (Recent Filing)$3.65M

Total Debt (Recent Filing)$1.80M

Price to Earnings (P/E)―

Beta2.25

Next Earnings

Nov 05, 2026

EPS Estimate

-1.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-26.72

Shares Outstanding6,252,319

10 Day Avg. Volume1,334,715

30 Day Avg. Volume10,088,102

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.33

Price to Sales (P/S)10.83

P/FCF Ratio-0.23

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$4.00

Price Target Upside90.48% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-12.15

Revenue Forecast (FY)$552.40K

Bulls Say, Bears Say

Bulls Say

International Commercial ExpansionPlanned joint ventures and international expansion targeting tuberculosis and HPV markets may open significant new revenue streams and expand commercial footprint.

Point-of-care PerformancePCR Pro's laboratory-grade diagnostic performance in a compact, low-cost device supports adoption in decentralized clinics and other point-of-care settings.

Technology PotentialAnalyst maintains that the company's Co‑Primer technology could differentiate the platform by enabling more specific and reliable nucleic acid detection.

Bears Say

Capital Access ConstraintsPotential delisting could impede access to capital markets, raising the likelihood of funding constraints that would hinder operations and growth plans.

Exchange Delisting RiskRisk of delisting from a major exchange prompted analysts to assign Hold ratings, reflecting increased marketability concerns for the shares.

Regulatory And Listing UncertaintyOngoing listing and regulatory uncertainty is undermining investor confidence and may suppress the stock's valuation despite product strengths.

Co-Diagnostics News

Co-Diagnostics submits FDA 510(k) premarket notification for Co-Dx PCR Flu test

Co-Diagnostics (CODX) announced that it has submitted a Dual 510(k) premarket notification, with a concurrent CLIA Waiver by...

16d ago

CODX

Co-Diagnostics joint venture CoSara provides ebola test kits for India studies

Co-Diagnostics (CODX) announced that CoSara Diagnostics, the company’s joint venture in India, has sent test kits of the...

25d ago

CODX

Co-Diagnostics Earnings Call: Progress Amid Cash Strain

Co-Diagnostics (($CODX)) has held its Q2 earnings call. Read on for the main highlights of the call. Co-Diagnostics’...

2h ago

CODX

Co-Diagnostics Inducement Agreement for New Warrant Financing

Co-Diagnostics ( ($CODX) ) has shared an update. On July 30, 2026, Co-Diagnostics entered into an inducement agreement...

22d ago

CODX

Co-Diagnostics Amends Equity Distribution, Extends Issuance Limits

Co-Diagnostics ( ($CODX) ) just unveiled an announcement. On July 27, 2026, Co-Diagnostics amended its October 20, 2025...

25d ago

CODX

Co-Diagnostics appoints Wes Lindsey as Chief Scientific Officer

Co-Diagnostics (CODX) appointed Wes Lindsey as its new Chief Scientific Officer. Lindsey holds a PhD in Genetics &...

1M ago

CODX

CDC raises Ebola Congo outbreak response to highest level, Reuters reports

The Centers for Disease Control raised its response to the Ebola outbreak in the Democratic Republic of Congo...

2M ago

CODX

GOVX

Co-Diagnostics signs distribution agreement for CO-Dx PCR Pro in Mexico

Co-Diagnostics (CODX) has entered into an exclusive distribution agreement with its partner in Mexico for the Co-Dx PCR...

2M ago

CODX

WHO reports drop in suspected Ebola cases in Africa, France 24 says

The World Health Organization, or WHO, scaled back the number of suspected Ebola cases in central Africa to...

3M ago

CODX

GOVX

Co-Diagnostics announces continued progress in Ebola PCR development program

Co-Diagnostics (CODX) announced continued progress in its Ebola PCR development program with joint venture CoSara Diagnostics. The program...

3M ago

CODX

Co-Diagnostics trading halted, volatility trading pause

09:35 EDT Co-Diagnostics (CODX) trading halted, volatility trading pause Published first on TheFly – the ultimate source for...

3M ago

CODX

Co-Diagnostics trading resumes

09:46 EDT Co-Diagnostics (CODX) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking...

3M ago

CODX

Co-Diagnostics files to sell 4.94M shares of common stock for holders

17:14 EDT Co-Diagnostics (CODX) files to sell 4.94M shares of common stock for holders Published first on TheFly...

3M ago

CODX

Co-Diagnostics Announces $3 Million Private Placement Financing

Co-Diagnostics ( ($CODX) ) has shared an announcement. On May 19, 2026, Co-Diagnostics entered into a $3.0 million...

3M ago

CODX

CODX FAQ

What was Co-Diagnostics Inc’s price range in the past 12 months?

Co-Diagnostics Inc lowest stock price was $0.94 and its highest was $46.50 in the past 12 months.

What is Co-Diagnostics Inc’s market cap?

Co-Diagnostics Inc’s market cap is $6.88M.

When is Co-Diagnostics Inc’s upcoming earnings report date?

Co-Diagnostics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 75 days.

How were Co-Diagnostics Inc’s earnings last quarter?

Co-Diagnostics Inc released its earnings results on Aug 13, 2026. The company reported -$1.46 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Co-Diagnostics Inc overvalued?

According to Wall Street analysts Co-Diagnostics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Co-Diagnostics Inc pay dividends?

Co-Diagnostics Inc does not currently pay dividends.

What is Co-Diagnostics Inc’s EPS estimate?

Co-Diagnostics Inc’s EPS estimate is -1.25.

How many shares outstanding does Co-Diagnostics Inc have?

Co-Diagnostics Inc has 6,252,319 shares outstanding.

What happened to Co-Diagnostics Inc’s price movement after its last earnings report?

Co-Diagnostics Inc reported an EPS of -$1.46 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.04%.

Which hedge fund is a major shareholder of Co-Diagnostics Inc?

Currently, no hedge funds are holding shares in CODX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Co-Diagnostics Inc

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Co-Diagnostics (CODX) Earnings & Revenues

Historic Earnings Reports

CODX Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call conveyed meaningful operational and regulatory progress — including a dual FDA submission for an upper respiratory multiplex assay, >1,400-patient clinical enrollment, >10,000 analytical PCR runs, TB program advancement toward ERPD, a blood-based Ebola proof-of-concept, strengthened international manufacturing partnerships, and reduced operating expenses that improved net loss and adjusted EBITDA. However, these positives are counterbalanced by a very low revenue base ($166K), a steep decline in cash to $3.6M (≈70% drop), continued operating losses, and materially reduced total assets. While execution milestones materially de-risk the technology and regulatory path, the company faces near-term liquidity and commercialization scaling risks.View all CODX earnings summaries

CODX Stock 12 Month Forecast

Average Price Target

$4.00

▲(90.48% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","14":"$14","3.5":"$3.5","10.5":"$10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.5,7,10.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,1.636923076923077,1.833846153846154,2.0307692307692307,2.2276923076923074,2.4246153846153846,2.6215384615384614,2.8184615384615386,3.0153846153846153,3.212307692307692,3.4092307692307693,3.606153846153846,3.803076923076923,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,1.636923076923077,1.833846153846154,2.0307692307692307,2.2276923076923074,2.4246153846153846,2.6215384615384614,2.8184615384615386,3.0153846153846153,3.212307692307692,3.4092307692307693,3.606153846153846,3.803076923076923,{"y":4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,1.636923076923077,1.833846153846154,2.0307692307692307,2.2276923076923074,2.4246153846153846,2.6215384615384614,2.8184615384615386,3.0153846153846153,3.212307692307692,3.4092307692307693,3.606153846153846,3.803076923076923,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.446,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.891,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.593,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":13.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.842,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.057,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.08,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >